217 related articles for article (PubMed ID: 24184335)
1. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.
Warlick ED; Paulson K; Brazauskas R; Zhong X; Miller AM; Camitta BM; George B; Savani BN; Ustun C; Marks DI; Waller EK; Baron F; Freytes CO; Socie G; Akpek G; Schouten HC; Lazarus HM; Horwitz EM; Koreth J; Cahn JY; Bornhauser M; Seftel M; Cairo MS; Laughlin MJ; Sabloff M; Ringdén O; Gale RP; Kamble RT; Vij R; Gergis U; Mathews V; Saber W; Chen YB; Liesveld JL; Cutler CS; Ghobadi A; Uy GL; Eapen M; Weisdorf DJ; Litzow MR
Biol Blood Marrow Transplant; 2014 Feb; 20(2):202-8. PubMed ID: 24184335
[TBL] [Abstract][Full Text] [Related]
2. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
3. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
[TBL] [Abstract][Full Text] [Related]
4. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M; Schliemann C; Schetelig J; Röllig C; Kramer M; Glass B; Platzbecker U; Burchert A; Hänel M; Müller LP; Klein S; Bug G; Beelen D; Rösler W; Schäfer-Eckart K; Schmid C; Jost E; Lenz G; Tischer J; Spiekermann K; Pfirrmann M; Serve H; Stölzel F; Alakel N; Middeke JM; Thiede C; Ehninger G; Berdel WE; Stelljes M
JAMA Oncol; 2023 Apr; 9(4):519-526. PubMed ID: 36757706
[TBL] [Abstract][Full Text] [Related]
10. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170
[TBL] [Abstract][Full Text] [Related]
12. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.
Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640
[TBL] [Abstract][Full Text] [Related]
13. Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
Yano S; Yokoyama H; Yanada M; Mori J; Aoki J; Ohashi K; Kanomori H; Ozawa Y; Sawa M; Nakamae H; Eto T; Ohta S; Tanaka J; Ichinohe T; Atsuta Y; Takami A
Bone Marrow Transplant; 2019 Dec; 54(12):2004-2012. PubMed ID: 31152148
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
15. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.
Walter RB; Sandmaier BM; Storer BE; Godwin CD; Buckley SA; Pagel JM; Sorror ML; Deeg HJ; Storb R; Appelbaum FR
Biol Blood Marrow Transplant; 2015 Feb; 21(2):373-8. PubMed ID: 25278455
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.
McCormack SE; Cao Q; Oran B; Weisdorf DJ; Warlick ED
Leuk Res; 2011 Jun; 35(6):757-61. PubMed ID: 21232793
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
18. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
[TBL] [Abstract][Full Text] [Related]
19. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.
Warlick ED; Peffault de Latour R; Shanley R; Robin M; Bejanyan N; Xhaard A; Brunstein C; Sicre de Fontbrune F; Ustun C; Weisdorf DJ; Socie G
Biol Blood Marrow Transplant; 2015 Feb; 21(2):357-63. PubMed ID: 25452032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
